Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia
Identifieur interne : 006796 ( PascalFrancis/Corpus ); précédent : 006795; suivant : 006797Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia
Auteurs : J. R. Passweg ; P. Tiberghien ; J.-Y. Cahn ; M. R. Vowels ; B. M. Camitta ; R. P. Gale ; R. H. Herzig ; D. Hoelzer ; M. M. Horowitz ; N. Ifrah ; J. P. Klein ; D. I. Marks ; N. K. C. Ramsay ; P. A. Rowlings ; D. J. Weisdorf ; M.-J. Zhang ; A. J. BarrettSource :
- Bone marrow transplantation : (Basingstoke) [ 0268-3369 ] ; 1998.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
T and B lineage ALL cells express different levels of HLA-class II antigens, which may serve as targets for graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL). The object of this study was to determine whether GVL effects after HLA-identical sibling bone marrow transplantation differed in T and B lineage ALL. We studied 1132 patients with ALL of T lineage (n = 416) or of B lineage (cALLa+) (n = 716) transplanted in first (n = 605) or second (n = 527) remission with bone marrow from an HLA-identical sibling donor, between 1982 and 1992, and reported to the IBMTR by 165 teams. Cox proportional hazards regression models were used to determine the relative risk (RR) of relapse in patients with acute (grades II-IV) or chronic GVHD vs patients without GVHD. Acute and chronic GVHD were considered as time-dependent covariates. Patients transplanted in first and second remission were analyzed separately. GVHD decreased relapse risks to a similar extent in T and B lineage ALL. For first remission transplants, relative risks of relapse for patients with vs those without GVHD was 0.34 for T lineage ALL and 0.44 for B lineage ALL. Corresponding relative risks in second remission transplants were 0.54 and 0.61. This study confirms earlier findings of an antileukemia effect of GVHD in ALL. This effect was similar in T lineage and B lineage ALL, despite probable differences in HLA-class II antigen expression.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 98-0124769 INIST |
|---|---|
| ET : | Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia |
| AU : | PASSWEG (J. R.); TIBERGHIEN (P.); CAHN (J.-Y.); VOWELS (M. R.); CAMITTA (B. M.); GALE (R. P.); HERZIG (R. H.); HOELZER (D.); HOROWITZ (M. M.); IFRAH (N.); KLEIN (J. P.); MARKS (D. I.); RAMSAY (N. K. C.); ROWLINGS (P. A.); WEISDORF (D. J.); ZHANG (M.-J.); BARRETT (A. J.) |
| AF : | International Bone Marrow Transplant Registry (IBMTR), Health Policy Institute, Medical College of Wisconsin/Milwaukee, WI/Etats-Unis (1 aut., 9 aut., 11 aut., 14 aut., 16 aut.); Etablissement de Transfusion Sanguine Franche-Comté/Besançon/France (2 aut.); Service d'Hématologie, Hôpital Jean Minjoz/Besançon/France (3 aut.); Bone Marrow Transplant Unit, Prince of Wales Children's Hospital/Randwick, NSW/Australie (4 aut.); Departments of Pediatrics and Medicine, Medical College of Wisconsin/Milwaukee, WI/Etats-Unis (5 aut.); Division of Bone Marrow and Stem Cell Transplantation, Salick Health Care, Inc./Los Angeles, CA/Etats-Unis (6 aut.); Division of Medical Oncology/Hematology, James Graham Brown Cancer Center, University of Louisville/Louisville, KY/Etats-Unis (7 aut.); Department of Hematology, Zentrum der Inneren Medizin, Universität Frankfurt/Frankfurt/Allemagne (8 aut.); Service des Maladies du Sang/Angers/France (10 aut.); Bone Marrow Transplant Program, Hahnemann University/Philadelphia, PA/Etats-Unis (12 aut.); Bone Marrow Transplant Program, University of Minnesota Hospital and Clinics/Minneapolis, MN/Etats-Unis (13 aut., 15 aut.); National Heart, Lung and Blood Institute, National Institutes of Health/Bethesda, MD/Etats-Unis (17 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Bone marrow transplantation : (Basingstoke); ISSN 0268-3369; Coden BMTRE9; Royaume-Uni; Da. 1998; Vol. 21; No. 2; Pp. 153-158; Bibl. 27 ref. |
| LA : | Anglais |
| EA : | T and B lineage ALL cells express different levels of HLA-class II antigens, which may serve as targets for graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL). The object of this study was to determine whether GVL effects after HLA-identical sibling bone marrow transplantation differed in T and B lineage ALL. We studied 1132 patients with ALL of T lineage (n = 416) or of B lineage (cALLa+) (n = 716) transplanted in first (n = 605) or second (n = 527) remission with bone marrow from an HLA-identical sibling donor, between 1982 and 1992, and reported to the IBMTR by 165 teams. Cox proportional hazards regression models were used to determine the relative risk (RR) of relapse in patients with acute (grades II-IV) or chronic GVHD vs patients without GVHD. Acute and chronic GVHD were considered as time-dependent covariates. Patients transplanted in first and second remission were analyzed separately. GVHD decreased relapse risks to a similar extent in T and B lineage ALL. For first remission transplants, relative risks of relapse for patients with vs those without GVHD was 0.34 for T lineage ALL and 0.44 for B lineage ALL. Corresponding relative risks in second remission transplants were 0.54 and 0.61. This study confirms earlier findings of an antileukemia effect of GVHD in ALL. This effect was similar in T lineage and B lineage ALL, despite probable differences in HLA-class II antigen expression. |
| CC : | 002B27D02 |
| FD : | Leucémie lymphoblastique; Réaction greffon leucémie; Réponse immune; Lymphocyte T; Lymphocyte B; Immunité cellulaire; Immunité humorale; Homme; Maladie greffon hôte; Récidive; Facteur risque; Aigu |
| FG : | Hémopathie maligne; Lymphoprolifératif syndrome; Immunopathologie |
| ED : | Acute lymphocytic leukemia; Graft versus leukemia reaction; Immune response; T-Lymphocyte; B-Lymphocyte; Cellular immunity; Humoral immunity; Human; Graft versus host reaction; Relapse; Risk factor; Acute |
| EG : | Malignant hemopathy; Lymphoproliferative syndrome; Immunopathology |
| SD : | Leucemia linfoblástica; Reacción injerto leucemia; Respuesta inmune; Linfocito T; Linfocito B; Inmunidad celular; Inmunidad humoral; Hombre; Enfermedad injerto huesped; Recaida; Factor riesgo; Agudo |
| LO : | INIST-21176.354000077979890080 |
| ID : | 98-0124769 |
Links to Exploration step
Pascal:98-0124769Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia</title><author><name sortKey="Passweg, J R" sort="Passweg, J R" uniqKey="Passweg J" first="J. R." last="Passweg">J. R. Passweg</name><affiliation><inist:fA14 i1="01"><s1>International Bone Marrow Transplant Registry (IBMTR), Health Policy Institute, Medical College of Wisconsin</s1><s2>Milwaukee, WI</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>11 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Tiberghien, P" sort="Tiberghien, P" uniqKey="Tiberghien P" first="P." last="Tiberghien">P. Tiberghien</name><affiliation><inist:fA14 i1="02"><s1>Etablissement de Transfusion Sanguine Franche-Comté</s1><s2>Besançon</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Cahn, J Y" sort="Cahn, J Y" uniqKey="Cahn J" first="J.-Y." last="Cahn">J.-Y. Cahn</name><affiliation><inist:fA14 i1="03"><s1>Service d'Hématologie, Hôpital Jean Minjoz</s1><s2>Besançon</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Vowels, M R" sort="Vowels, M R" uniqKey="Vowels M" first="M. R." last="Vowels">M. R. Vowels</name><affiliation><inist:fA14 i1="04"><s1>Bone Marrow Transplant Unit, Prince of Wales Children's Hospital</s1><s2>Randwick, NSW</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Camitta, B M" sort="Camitta, B M" uniqKey="Camitta B" first="B. M." last="Camitta">B. M. Camitta</name><affiliation><inist:fA14 i1="05"><s1>Departments of Pediatrics and Medicine, Medical College of Wisconsin</s1><s2>Milwaukee, WI</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gale, R P" sort="Gale, R P" uniqKey="Gale R" first="R. P." last="Gale">R. P. Gale</name><affiliation><inist:fA14 i1="06"><s1>Division of Bone Marrow and Stem Cell Transplantation, Salick Health Care, Inc.</s1><s2>Los Angeles, CA</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Herzig, R H" sort="Herzig, R H" uniqKey="Herzig R" first="R. H." last="Herzig">R. H. Herzig</name><affiliation><inist:fA14 i1="07"><s1>Division of Medical Oncology/Hematology, James Graham Brown Cancer Center, University of Louisville</s1><s2>Louisville, KY</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hoelzer, D" sort="Hoelzer, D" uniqKey="Hoelzer D" first="D." last="Hoelzer">D. Hoelzer</name><affiliation><inist:fA14 i1="08"><s1>Department of Hematology, Zentrum der Inneren Medizin, Universität Frankfurt</s1><s2>Frankfurt</s2><s3>DEU</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Horowitz, M M" sort="Horowitz, M M" uniqKey="Horowitz M" first="M. M." last="Horowitz">M. M. Horowitz</name><affiliation><inist:fA14 i1="01"><s1>International Bone Marrow Transplant Registry (IBMTR), Health Policy Institute, Medical College of Wisconsin</s1><s2>Milwaukee, WI</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>11 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ifrah, N" sort="Ifrah, N" uniqKey="Ifrah N" first="N." last="Ifrah">N. Ifrah</name><affiliation><inist:fA14 i1="09"><s1>Service des Maladies du Sang</s1><s2>Angers</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Klein, J P" sort="Klein, J P" uniqKey="Klein J" first="J. P." last="Klein">J. P. Klein</name><affiliation><inist:fA14 i1="01"><s1>International Bone Marrow Transplant Registry (IBMTR), Health Policy Institute, Medical College of Wisconsin</s1><s2>Milwaukee, WI</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>11 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Marks, D I" sort="Marks, D I" uniqKey="Marks D" first="D. I." last="Marks">D. I. Marks</name><affiliation><inist:fA14 i1="10"><s1>Bone Marrow Transplant Program, Hahnemann University</s1><s2>Philadelphia, PA</s2><s3>USA</s3><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ramsay, N K C" sort="Ramsay, N K C" uniqKey="Ramsay N" first="N. K. C." last="Ramsay">N. K. C. Ramsay</name><affiliation><inist:fA14 i1="11"><s1>Bone Marrow Transplant Program, University of Minnesota Hospital and Clinics</s1><s2>Minneapolis, MN</s2><s3>USA</s3><sZ>13 aut.</sZ><sZ>15 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rowlings, P A" sort="Rowlings, P A" uniqKey="Rowlings P" first="P. A." last="Rowlings">P. A. Rowlings</name><affiliation><inist:fA14 i1="01"><s1>International Bone Marrow Transplant Registry (IBMTR), Health Policy Institute, Medical College of Wisconsin</s1><s2>Milwaukee, WI</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>11 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Weisdorf, D J" sort="Weisdorf, D J" uniqKey="Weisdorf D" first="D. J." last="Weisdorf">D. J. Weisdorf</name><affiliation><inist:fA14 i1="11"><s1>Bone Marrow Transplant Program, University of Minnesota Hospital and Clinics</s1><s2>Minneapolis, MN</s2><s3>USA</s3><sZ>13 aut.</sZ><sZ>15 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zhang, M J" sort="Zhang, M J" uniqKey="Zhang M" first="M.-J." last="Zhang">M.-J. Zhang</name><affiliation><inist:fA14 i1="01"><s1>International Bone Marrow Transplant Registry (IBMTR), Health Policy Institute, Medical College of Wisconsin</s1><s2>Milwaukee, WI</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>11 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Barrett, A J" sort="Barrett, A J" uniqKey="Barrett A" first="A. J." last="Barrett">A. J. Barrett</name><affiliation><inist:fA14 i1="12"><s1>National Heart, Lung and Blood Institute, National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">98-0124769</idno><date when="1998">1998</date><idno type="stanalyst">PASCAL 98-0124769 INIST</idno><idno type="RBID">Pascal:98-0124769</idno><idno type="wicri:Area/PascalFrancis/Corpus">006796</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia</title><author><name sortKey="Passweg, J R" sort="Passweg, J R" uniqKey="Passweg J" first="J. R." last="Passweg">J. R. Passweg</name><affiliation><inist:fA14 i1="01"><s1>International Bone Marrow Transplant Registry (IBMTR), Health Policy Institute, Medical College of Wisconsin</s1><s2>Milwaukee, WI</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>11 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Tiberghien, P" sort="Tiberghien, P" uniqKey="Tiberghien P" first="P." last="Tiberghien">P. Tiberghien</name><affiliation><inist:fA14 i1="02"><s1>Etablissement de Transfusion Sanguine Franche-Comté</s1><s2>Besançon</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Cahn, J Y" sort="Cahn, J Y" uniqKey="Cahn J" first="J.-Y." last="Cahn">J.-Y. Cahn</name><affiliation><inist:fA14 i1="03"><s1>Service d'Hématologie, Hôpital Jean Minjoz</s1><s2>Besançon</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Vowels, M R" sort="Vowels, M R" uniqKey="Vowels M" first="M. R." last="Vowels">M. R. Vowels</name><affiliation><inist:fA14 i1="04"><s1>Bone Marrow Transplant Unit, Prince of Wales Children's Hospital</s1><s2>Randwick, NSW</s2><s3>AUS</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Camitta, B M" sort="Camitta, B M" uniqKey="Camitta B" first="B. M." last="Camitta">B. M. Camitta</name><affiliation><inist:fA14 i1="05"><s1>Departments of Pediatrics and Medicine, Medical College of Wisconsin</s1><s2>Milwaukee, WI</s2><s3>USA</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gale, R P" sort="Gale, R P" uniqKey="Gale R" first="R. P." last="Gale">R. P. Gale</name><affiliation><inist:fA14 i1="06"><s1>Division of Bone Marrow and Stem Cell Transplantation, Salick Health Care, Inc.</s1><s2>Los Angeles, CA</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Herzig, R H" sort="Herzig, R H" uniqKey="Herzig R" first="R. H." last="Herzig">R. H. Herzig</name><affiliation><inist:fA14 i1="07"><s1>Division of Medical Oncology/Hematology, James Graham Brown Cancer Center, University of Louisville</s1><s2>Louisville, KY</s2><s3>USA</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hoelzer, D" sort="Hoelzer, D" uniqKey="Hoelzer D" first="D." last="Hoelzer">D. Hoelzer</name><affiliation><inist:fA14 i1="08"><s1>Department of Hematology, Zentrum der Inneren Medizin, Universität Frankfurt</s1><s2>Frankfurt</s2><s3>DEU</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Horowitz, M M" sort="Horowitz, M M" uniqKey="Horowitz M" first="M. M." last="Horowitz">M. M. Horowitz</name><affiliation><inist:fA14 i1="01"><s1>International Bone Marrow Transplant Registry (IBMTR), Health Policy Institute, Medical College of Wisconsin</s1><s2>Milwaukee, WI</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>11 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ifrah, N" sort="Ifrah, N" uniqKey="Ifrah N" first="N." last="Ifrah">N. Ifrah</name><affiliation><inist:fA14 i1="09"><s1>Service des Maladies du Sang</s1><s2>Angers</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Klein, J P" sort="Klein, J P" uniqKey="Klein J" first="J. P." last="Klein">J. P. Klein</name><affiliation><inist:fA14 i1="01"><s1>International Bone Marrow Transplant Registry (IBMTR), Health Policy Institute, Medical College of Wisconsin</s1><s2>Milwaukee, WI</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>11 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Marks, D I" sort="Marks, D I" uniqKey="Marks D" first="D. I." last="Marks">D. I. Marks</name><affiliation><inist:fA14 i1="10"><s1>Bone Marrow Transplant Program, Hahnemann University</s1><s2>Philadelphia, PA</s2><s3>USA</s3><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ramsay, N K C" sort="Ramsay, N K C" uniqKey="Ramsay N" first="N. K. C." last="Ramsay">N. K. C. Ramsay</name><affiliation><inist:fA14 i1="11"><s1>Bone Marrow Transplant Program, University of Minnesota Hospital and Clinics</s1><s2>Minneapolis, MN</s2><s3>USA</s3><sZ>13 aut.</sZ><sZ>15 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rowlings, P A" sort="Rowlings, P A" uniqKey="Rowlings P" first="P. A." last="Rowlings">P. A. Rowlings</name><affiliation><inist:fA14 i1="01"><s1>International Bone Marrow Transplant Registry (IBMTR), Health Policy Institute, Medical College of Wisconsin</s1><s2>Milwaukee, WI</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>11 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Weisdorf, D J" sort="Weisdorf, D J" uniqKey="Weisdorf D" first="D. J." last="Weisdorf">D. J. Weisdorf</name><affiliation><inist:fA14 i1="11"><s1>Bone Marrow Transplant Program, University of Minnesota Hospital and Clinics</s1><s2>Minneapolis, MN</s2><s3>USA</s3><sZ>13 aut.</sZ><sZ>15 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zhang, M J" sort="Zhang, M J" uniqKey="Zhang M" first="M.-J." last="Zhang">M.-J. Zhang</name><affiliation><inist:fA14 i1="01"><s1>International Bone Marrow Transplant Registry (IBMTR), Health Policy Institute, Medical College of Wisconsin</s1><s2>Milwaukee, WI</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>11 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Barrett, A J" sort="Barrett, A J" uniqKey="Barrett A" first="A. J." last="Barrett">A. J. Barrett</name><affiliation><inist:fA14 i1="12"><s1>National Heart, Lung and Blood Institute, National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Bone marrow transplantation : (Basingstoke)</title><title level="j" type="abbreviated">Bone marrow transplant. : (Basingstoke)</title><idno type="ISSN">0268-3369</idno><imprint><date when="1998">1998</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Bone marrow transplantation : (Basingstoke)</title><title level="j" type="abbreviated">Bone marrow transplant. : (Basingstoke)</title><idno type="ISSN">0268-3369</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute</term><term>Acute lymphocytic leukemia</term><term>B-Lymphocyte</term><term>Cellular immunity</term><term>Graft versus host reaction</term><term>Graft versus leukemia reaction</term><term>Human</term><term>Humoral immunity</term><term>Immune response</term><term>Relapse</term><term>Risk factor</term><term>T-Lymphocyte</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Leucémie lymphoblastique</term><term>Réaction greffon leucémie</term><term>Réponse immune</term><term>Lymphocyte T</term><term>Lymphocyte B</term><term>Immunité cellulaire</term><term>Immunité humorale</term><term>Homme</term><term>Maladie greffon hôte</term><term>Récidive</term><term>Facteur risque</term><term>Aigu</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">T and B lineage ALL cells express different levels of HLA-class II antigens, which may serve as targets for graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL). The object of this study was to determine whether GVL effects after HLA-identical sibling bone marrow transplantation differed in T and B lineage ALL. We studied 1132 patients with ALL of T lineage (n = 416) or of B lineage (cALLa<sup>+</sup>) (n = 716) transplanted in first (n = 605) or second (n = 527) remission with bone marrow from an HLA-identical sibling donor, between 1982 and 1992, and reported to the IBMTR by 165 teams. Cox proportional hazards regression models were used to determine the relative risk (RR) of relapse in patients with acute (grades II-IV) or chronic GVHD vs patients without GVHD. Acute and chronic GVHD were considered as time-dependent covariates. Patients transplanted in first and second remission were analyzed separately. GVHD decreased relapse risks to a similar extent in T and B lineage ALL. For first remission transplants, relative risks of relapse for patients with vs those without GVHD was 0.34 for T lineage ALL and 0.44 for B lineage ALL. Corresponding relative risks in second remission transplants were 0.54 and 0.61. This study confirms earlier findings of an antileukemia effect of GVHD in ALL. This effect was similar in T lineage and B lineage ALL, despite probable differences in HLA-class II antigen expression.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0268-3369</s0></fA01><fA02 i1="01"><s0>BMTRE9</s0></fA02><fA03 i2="1"><s0>Bone marrow transplant. : (Basingstoke)</s0></fA03><fA05><s2>21</s2></fA05><fA06><s2>2</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia</s1></fA08><fA11 i1="01" i2="1"><s1>PASSWEG (J. R.)</s1></fA11><fA11 i1="02" i2="1"><s1>TIBERGHIEN (P.)</s1></fA11><fA11 i1="03" i2="1"><s1>CAHN (J.-Y.)</s1></fA11><fA11 i1="04" i2="1"><s1>VOWELS (M. R.)</s1></fA11><fA11 i1="05" i2="1"><s1>CAMITTA (B. M.)</s1></fA11><fA11 i1="06" i2="1"><s1>GALE (R. P.)</s1></fA11><fA11 i1="07" i2="1"><s1>HERZIG (R. H.)</s1></fA11><fA11 i1="08" i2="1"><s1>HOELZER (D.)</s1></fA11><fA11 i1="09" i2="1"><s1>HOROWITZ (M. M.)</s1></fA11><fA11 i1="10" i2="1"><s1>IFRAH (N.)</s1></fA11><fA11 i1="11" i2="1"><s1>KLEIN (J. P.)</s1></fA11><fA11 i1="12" i2="1"><s1>MARKS (D. I.)</s1></fA11><fA11 i1="13" i2="1"><s1>RAMSAY (N. K. C.)</s1></fA11><fA11 i1="14" i2="1"><s1>ROWLINGS (P. A.)</s1></fA11><fA11 i1="15" i2="1"><s1>WEISDORF (D. J.)</s1></fA11><fA11 i1="16" i2="1"><s1>ZHANG (M.-J.)</s1></fA11><fA11 i1="17" i2="1"><s1>BARRETT (A. J.)</s1></fA11><fA14 i1="01"><s1>International Bone Marrow Transplant Registry (IBMTR), Health Policy Institute, Medical College of Wisconsin</s1><s2>Milwaukee, WI</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>11 aut.</sZ><sZ>14 aut.</sZ><sZ>16 aut.</sZ></fA14><fA14 i1="02"><s1>Etablissement de Transfusion Sanguine Franche-Comté</s1><s2>Besançon</s2><s3>FRA</s3><sZ>2 aut.</sZ></fA14><fA14 i1="03"><s1>Service d'Hématologie, Hôpital Jean Minjoz</s1><s2>Besançon</s2><s3>FRA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Bone Marrow Transplant Unit, Prince of Wales Children's Hospital</s1><s2>Randwick, NSW</s2><s3>AUS</s3><sZ>4 aut.</sZ></fA14><fA14 i1="05"><s1>Departments of Pediatrics and Medicine, Medical College of Wisconsin</s1><s2>Milwaukee, WI</s2><s3>USA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="06"><s1>Division of Bone Marrow and Stem Cell Transplantation, Salick Health Care, Inc.</s1><s2>Los Angeles, CA</s2><s3>USA</s3><sZ>6 aut.</sZ></fA14><fA14 i1="07"><s1>Division of Medical Oncology/Hematology, James Graham Brown Cancer Center, University of Louisville</s1><s2>Louisville, KY</s2><s3>USA</s3><sZ>7 aut.</sZ></fA14><fA14 i1="08"><s1>Department of Hematology, Zentrum der Inneren Medizin, Universität Frankfurt</s1><s2>Frankfurt</s2><s3>DEU</s3><sZ>8 aut.</sZ></fA14><fA14 i1="09"><s1>Service des Maladies du Sang</s1><s2>Angers</s2><s3>FRA</s3><sZ>10 aut.</sZ></fA14><fA14 i1="10"><s1>Bone Marrow Transplant Program, Hahnemann University</s1><s2>Philadelphia, PA</s2><s3>USA</s3><sZ>12 aut.</sZ></fA14><fA14 i1="11"><s1>Bone Marrow Transplant Program, University of Minnesota Hospital and Clinics</s1><s2>Minneapolis, MN</s2><s3>USA</s3><sZ>13 aut.</sZ><sZ>15 aut.</sZ></fA14><fA14 i1="12"><s1>National Heart, Lung and Blood Institute, National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>17 aut.</sZ></fA14><fA20><s1>153-158</s1></fA20><fA21><s1>1998</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>21176</s2><s5>354000077979890080</s5></fA43><fA44><s0>0000</s0><s1>© 1998 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>27 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>98-0124769</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i2="1"><s0>Bone marrow transplantation : (Basingstoke)</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>T and B lineage ALL cells express different levels of HLA-class II antigens, which may serve as targets for graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL). The object of this study was to determine whether GVL effects after HLA-identical sibling bone marrow transplantation differed in T and B lineage ALL. We studied 1132 patients with ALL of T lineage (n = 416) or of B lineage (cALLa<sup>+</sup>) (n = 716) transplanted in first (n = 605) or second (n = 527) remission with bone marrow from an HLA-identical sibling donor, between 1982 and 1992, and reported to the IBMTR by 165 teams. Cox proportional hazards regression models were used to determine the relative risk (RR) of relapse in patients with acute (grades II-IV) or chronic GVHD vs patients without GVHD. Acute and chronic GVHD were considered as time-dependent covariates. Patients transplanted in first and second remission were analyzed separately. GVHD decreased relapse risks to a similar extent in T and B lineage ALL. For first remission transplants, relative risks of relapse for patients with vs those without GVHD was 0.34 for T lineage ALL and 0.44 for B lineage ALL. Corresponding relative risks in second remission transplants were 0.54 and 0.61. This study confirms earlier findings of an antileukemia effect of GVHD in ALL. This effect was similar in T lineage and B lineage ALL, despite probable differences in HLA-class II antigen expression.</s0></fC01><fC02 i1="01" i2="X"><s0>002B27D02</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Leucémie lymphoblastique</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Acute lymphocytic leukemia</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Leucemia linfoblástica</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Réaction greffon leucémie</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Graft versus leukemia reaction</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Reacción injerto leucemia</s0><s5>04</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Réponse immune</s0><s5>05</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Immune response</s0><s5>05</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Respuesta inmune</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Lymphocyte T</s0><s5>06</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>T-Lymphocyte</s0><s5>06</s5><s6>«T»-Lymphocyte</s6></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Linfocito T</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Lymphocyte B</s0><s5>07</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>B-Lymphocyte</s0><s5>07</s5><s6>«B»-Lymphocyte</s6></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Linfocito B</s0><s5>07</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Immunité cellulaire</s0><s5>08</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Cellular immunity</s0><s5>08</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Inmunidad celular</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Immunité humorale</s0><s5>09</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Humoral immunity</s0><s5>09</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Inmunidad humoral</s0><s5>09</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0><s5>10</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Human</s0><s5>10</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0><s5>10</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Maladie greffon hôte</s0><s5>13</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Graft versus host reaction</s0><s5>13</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Enfermedad injerto huesped</s0><s5>13</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Récidive</s0><s5>17</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Relapse</s0><s5>17</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Recaida</s0><s5>17</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Facteur risque</s0><s5>18</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Risk factor</s0><s5>18</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Factor riesgo</s0><s5>18</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Aigu</s0><s5>25</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Acute</s0><s5>25</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Agudo</s0><s5>25</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Hémopathie maligne</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Malignant hemopathy</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Hemopatía maligna</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Lymphoprolifératif syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Lymphoproliferative syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Linfoproliferativo síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Immunopathologie</s0><s5>69</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Immunopathology</s0><s5>69</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Inmunopatología</s0><s5>69</s5></fC07><fN21><s1>075</s1></fN21></pA></standard><server><NO>PASCAL 98-0124769 INIST</NO><ET>Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia</ET><AU>PASSWEG (J. R.); TIBERGHIEN (P.); CAHN (J.-Y.); VOWELS (M. R.); CAMITTA (B. M.); GALE (R. P.); HERZIG (R. H.); HOELZER (D.); HOROWITZ (M. M.); IFRAH (N.); KLEIN (J. P.); MARKS (D. I.); RAMSAY (N. K. C.); ROWLINGS (P. A.); WEISDORF (D. J.); ZHANG (M.-J.); BARRETT (A. J.)</AU><AF>International Bone Marrow Transplant Registry (IBMTR), Health Policy Institute, Medical College of Wisconsin/Milwaukee, WI/Etats-Unis (1 aut., 9 aut., 11 aut., 14 aut., 16 aut.); Etablissement de Transfusion Sanguine Franche-Comté/Besançon/France (2 aut.); Service d'Hématologie, Hôpital Jean Minjoz/Besançon/France (3 aut.); Bone Marrow Transplant Unit, Prince of Wales Children's Hospital/Randwick, NSW/Australie (4 aut.); Departments of Pediatrics and Medicine, Medical College of Wisconsin/Milwaukee, WI/Etats-Unis (5 aut.); Division of Bone Marrow and Stem Cell Transplantation, Salick Health Care, Inc./Los Angeles, CA/Etats-Unis (6 aut.); Division of Medical Oncology/Hematology, James Graham Brown Cancer Center, University of Louisville/Louisville, KY/Etats-Unis (7 aut.); Department of Hematology, Zentrum der Inneren Medizin, Universität Frankfurt/Frankfurt/Allemagne (8 aut.); Service des Maladies du Sang/Angers/France (10 aut.); Bone Marrow Transplant Program, Hahnemann University/Philadelphia, PA/Etats-Unis (12 aut.); Bone Marrow Transplant Program, University of Minnesota Hospital and Clinics/Minneapolis, MN/Etats-Unis (13 aut., 15 aut.); National Heart, Lung and Blood Institute, National Institutes of Health/Bethesda, MD/Etats-Unis (17 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Bone marrow transplantation : (Basingstoke); ISSN 0268-3369; Coden BMTRE9; Royaume-Uni; Da. 1998; Vol. 21; No. 2; Pp. 153-158; Bibl. 27 ref.</SO><LA>Anglais</LA><EA>T and B lineage ALL cells express different levels of HLA-class II antigens, which may serve as targets for graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL). The object of this study was to determine whether GVL effects after HLA-identical sibling bone marrow transplantation differed in T and B lineage ALL. We studied 1132 patients with ALL of T lineage (n = 416) or of B lineage (cALLa<sup>+</sup>) (n = 716) transplanted in first (n = 605) or second (n = 527) remission with bone marrow from an HLA-identical sibling donor, between 1982 and 1992, and reported to the IBMTR by 165 teams. Cox proportional hazards regression models were used to determine the relative risk (RR) of relapse in patients with acute (grades II-IV) or chronic GVHD vs patients without GVHD. Acute and chronic GVHD were considered as time-dependent covariates. Patients transplanted in first and second remission were analyzed separately. GVHD decreased relapse risks to a similar extent in T and B lineage ALL. For first remission transplants, relative risks of relapse for patients with vs those without GVHD was 0.34 for T lineage ALL and 0.44 for B lineage ALL. Corresponding relative risks in second remission transplants were 0.54 and 0.61. This study confirms earlier findings of an antileukemia effect of GVHD in ALL. This effect was similar in T lineage and B lineage ALL, despite probable differences in HLA-class II antigen expression.</EA><CC>002B27D02</CC><FD>Leucémie lymphoblastique; Réaction greffon leucémie; Réponse immune; Lymphocyte T; Lymphocyte B; Immunité cellulaire; Immunité humorale; Homme; Maladie greffon hôte; Récidive; Facteur risque; Aigu</FD><FG>Hémopathie maligne; Lymphoprolifératif syndrome; Immunopathologie</FG><ED>Acute lymphocytic leukemia; Graft versus leukemia reaction; Immune response; T-Lymphocyte; B-Lymphocyte; Cellular immunity; Humoral immunity; Human; Graft versus host reaction; Relapse; Risk factor; Acute</ED><EG>Malignant hemopathy; Lymphoproliferative syndrome; Immunopathology</EG><SD>Leucemia linfoblástica; Reacción injerto leucemia; Respuesta inmune; Linfocito T; Linfocito B; Inmunidad celular; Inmunidad humoral; Hombre; Enfermedad injerto huesped; Recaida; Factor riesgo; Agudo</SD><LO>INIST-21176.354000077979890080</LO><ID>98-0124769</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006796 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 006796 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:98-0124769
|texte= Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia
}}
| This area was generated with Dilib version V0.6.33. |  |